Approaches to type 1 diabetes prevention by intervention in cytokine immunoregulatory circuits

International Journal of Experimental Diabetes Research

Volumn 2, Issue 1, 2001, Pages 3-17

  Suarez Pinzon, Wilma L ^a   Rabinovitch, Alex ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Autoimmunity; Cytokines; Immunoregulation; Type 1 diabetes

Indexed keywords

AUTOANTIGEN; CYTOKINE; FREUND ADJUVANT; GAMMA INTERFERON; GLUCOSE; GLUTAMATE DECARBOXYLASE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DESTRUCTION; CELL SPECIFICITY; CLINICAL FEATURE; FEMALE; HYPERGLYCEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULITIS; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0035692747     PISSN: 15604284     EISSN: None     Source Type: Journal    
DOI: 10.1155/EDR.2001.3     Document Type: Review

References (154)

1. Insulin-dependent diabetes mellitus as an autoimmune disease
2. The primary lesion theory of autoimmunity: A speculative hypothesis
3. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation
4. Autoimmune polyendocrine failure-Type 1 (insulin-dependent) diabetes mellitus and hypothyroidism-after allogeneic bone marrow transplantation in a patient with lymphoblastic leukaemia
5. Discussion remark to Session 24: BMT in autoimmune diseases
6. Detection of cell-mediated immunity in type I diabetes mellitus
7. Transfer of Type 1 (insulin-dependent) diabetes mellitus associated autoimmunity to mice with severe combined immunodeficiency (SCID)
8. Immunopathogenesis of diabetes mellitus
9. Influence of microbial agents on the development and prevention of autoimmune diabetes
10. Acceleration of the onset of diabetes in NOD mice by thymectomy at weaning
11. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide
12. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice
13. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells
14. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone
15. Evidence of CD4+ regulatory T cells in the nonobese diabetic male mouse
16. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice
17. A protective NOD islet-infiltrating CD8+ T cell clone, I.W. 2.15, has in vitro immunosuppressive properties
18. Islet-infiltrating T cell clones from non-obese diabetic mice that promote or prevent accelerated onset diabetes
19. An anergic, islet-infiltrating T-cell clone that suppresses murine diabetes secretes a factor that blocks interleukin 2/interleukin 4-dependent proliferation
20. Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: Transfer of protection by splenic T cells
21. Depletion of RT6.1+ T lymphocytes induces diabetes in resistant biobreeding/Worcester (BB/W) rats
22. Lymphocyte transfusions prevent diabetes in the Bio-Breeding/Worcester rat
23. Detection and measurement of cytokines
24. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins
25. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays and monoclonal antibodies
26. Purified protein derivative (PPD) of Mycobacterium tuberculosis and excretory-secretory antigen(s) (TES) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T cytokine production
27. The expanding universe of T-cell subsets: Th1, Th2 and more
28. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties
29. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
30. Lymphokine production by human T cells in disease states
31. Differential regulation of murine T lymphocyte subsets
32. Acquisition of lymphokine-producing phenotype by CD4+ T-cells
33. Interleukin 10
34. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
35. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the upregulation of B7 expression
36. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo
37. Complexity or coherence? Cytokine secretion by B cells
38. The Th1-Th2 hypothesis of HIV infection: New insights
39. Subsets of CD4+ T-cells and their roles in the induction and prevention of autoimmunity
40. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential
41. low CD4+ cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse
42. GAD-reactive CD4+ Th1 cells induce diabetes in NOD/SCID mice
43. + β islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice
44. A new type of CD4+ suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice
45. Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse
46. In vivo activity and in vitro specificity of CD4+ Th1 and Th2 T cells derived from the spleens of diabetic NOD mice
47. T helper cell subsets in insulin-dependent diabetes
48. +CD4CD8 (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10
49. +-like thymocytes in the NOD mouse
50. +CD4CD8 thymocytes
51. Interleukin-4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice
52. + thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse
53. Preferential infiltration of macrophages during early stages of insulitis in diabetes-prone BB rats
54. Dendritic cells and scavenger macrophages in pancreatic islets of prediabetic BB rats
55. Immunohistochemical characterization of monocyte-macrophages and dendritic cells involved in the initiation of insulitis and beta-cell destruction in NOD mice
56. Administration of silica prevents diabetes in BB rats
57. Evidence for initial involvement of macrophages in development of insulitis in NOD mice
58. The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice
59. + T- cells in T-cell receptor transgenic NOD mice
60. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: Analysis of a new "speed congenic" stock of NOD.Ig mu null mice
61. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice
62. Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in non-obese diabetic mice
63. Presentation of -cell antigens to CD4+ and CD8+ T-cells of nonobese diabetic mice
64. MHC class-II molecules and autoimmunity
65. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity
66. Prevention of diabetes in NOD mice by a mutated I-Ab transgene
67. Roles of multiple accessory molecules in T-cell activation
68. CD40 and CD154 in cell-mediated immunity
69. Expression of the costimulator molecule B7-1 in pancreatic β-cells accelerates diabetes in the NOD mouse
70. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
71. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice
72. Expression of intercellular adhesion molecule 1 on pancreatic beta-cells accelerates beta-cell destruction by cytotoxic T-cells in murine autoimmune diabetes
73. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-/intercellular adhesion molecule-1 pathway
74. Soluble forms of intercellular adhesion molecule-1 inhibit insulitis and onset of autoimmune diabetes
75. + lymphocytes
76. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice
77. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an αβ T-cell-receptor transgenic system
78. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T-cells from T-cell receptor transgenic mice
79. Prevention of type I diabetes in nonobese diabetic mice by virus infection
80. Inhibition of diabetes in BB rats by virus infection
81. Persistent MHV (mouse hepatitis virus) infection reduces the incidence of diabetes mellitus in nonobese diabetic mice
82. Paradoxical lessening of autoimmune processes in nonobese diabetic mice after infection with the diabetogenic variant of encephalomyocarditis virus
83. Suppression of development of diabetes in NOD mice by lactate dehydrogenase virus infection
84. Streptococcal preparation (OK-432) inhibits development of type I diabetes in NOD mice
85. Treatment with streptococcal preparation (OK-432) suppresses anti-islet autoimmunity and prevents diabetes in BB rats
86. Prevention of autoimmune type I diabetes by CD4+ suppressor T-cells in superantigen-treated nonobese diabetic mice
87. An immunomodulating protein Ling Zhi-8 (LZ-8) prevents insulitis in nonobese diabetic mice
88. Induction and therapy of autoimmune diabetes in the nonobese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein
89. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy
90. Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant
91. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice
92. Studies of concanavalin A in nonobese diabetic mice. I. Prevention of insulin-dependent diabetes
93. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy
94. A T-cell dormant state in the autoimmune process of nonobese diabetic mice treated with complete Freund's adjuvant
95. Mechanisms of complete Freund's adjuvant protection against diabetes in BB rats: Induction of non-specific suppressor cells
96. Complete Freund's adjuvant-induced T-cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice
97. Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mouse. I. Generation of suppressor macrophages in spleen cells of BCG-vaccinated mice
98. Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mice. II. Suppression of pathogenesis by macrophage transfer from BCG-vaccinated mice
99. BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice
100. Altered cytokine activity in adjuvant inhibition of autoimmune diabetes
101. Protection from autoimmune diabetes by adjuvant therapy in the non-obese diabetic mouse: The role of interleukin-4 and interleukin-10
102. Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: Interleukin 2 and interferon gamma mRNA expression correlate with graft rejection and interleukin 10 with graft survival
103. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice: Analysis of cytokine mRNA expression in the graft
104. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice
105. Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans
106. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice
107. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice
108. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice
109. Recombinant human IL-10 (rHU IL-10) prevents the onset of diabetes in the nonobese diabetic (NOD) mouse
110. Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes
111. CD28 costimulation promotes the production of Th2 cytokines
112. CD28/B7 regulation of Th1 and Th2 subsets in the development and progression of autoimmune diabetes
113. Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4 dependent mechanism
114. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes
115. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cells death
116. Differential ability of T cell subsets to undergo activation-induced cell death
117. Unequal death in T helper (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis
118. Th1 to Th2 cytokine shifts in NOD mice: Sometimes an outcome, rather than the cause of diabetes resistance elicited by immunostimulation
119. Interferon eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells
120. Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models
121. How do monoclonal antibodies induce tolerance? A role for infectious tolerance?
122. Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic β cells
123. IFN-γ is critical for long-term allograft survival induced by blocking the CD28 and CD40L T cell costimulation pathways
124. Biphasic roles for IFN in islet allograft immunity and tolerance
125. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice
126. IL-2 knockout recipient mice reject islet cell allografts
127. Extreme Th1 bias of regulatory V24JQ T cells in type 1 diabetes
128. A defect in interleukin 12-induced activation and interferon γ secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus
129. Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice
130. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation?
131. + cells in the pathogenesis of organ-specific autoimmune diseases
132. The Th1/Th2 balance in autoimmunity
133. The nonobese diabetic mouse as a model of autoimmune diabetes: Immune dysregulation gets the NOD
134. Interleukin-4 deficiency does not exacerbate disease in NOD mice
135. Schistosoma mansoni in IL-4-deficient mice
136. Susceptibility to Leishmani major infection in interleukin-4-deficient mice
137. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes
138. Immune response to glutamic acid decarboxylase correlates with insulitis in nonobese diabetic mice
139. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice
140. Induction of GAD65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope-dependent
141. Antigen-specific mediated suppression of β cell autoimmunity by plasmid DNA vaccination
142. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes
143. Quantitation of glutamic acid decarboxylase autoantibody levels in prospectively evaluated relatives of patients with type I diabetes
144. Insulin prophylaxis in insulin-dependent diabetes mellitus. Immunological rationale and therapeutic use
145. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin
146. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-chain (9-23)
147. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines
148. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes
149. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance
150. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-β, and prostaglandin-E
151. Suppression of diabetes in NOD mice by oral administration of porcine insulin
152. + T cells that suppress adoptive transfer of diabetes
153. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes
154. Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes